Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment

(2012) D. H. Fagan et al.   CANCER RESEARCH

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis

(2011) Y.-C. Lee et al.   CANCER RESEARCH

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

(2011) Giovanni Ligresti et al.   CELL CYCLE

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

(2011) Timothy A Yap et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

(2011) Andreas Varkaris et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer

(2011) F. Dayyani et al.   JNCI-Journal of the National Cancer Institute

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

PC3 is a cell line characteristic of prostatic small cell carcinoma

(2011) Sheng Tai et al.   PROSTATE

Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling

(2010) R. S. Wahdan-Alaswad et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

(2010) Kate Vandyke et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis

(2010) S. A. Rabbani et al.   MOLECULAR CANCER THERAPEUTICS

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress

(2009) S. Kopetz et al.   CANCER RESEARCH

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

Targeting of Bone-Derived Insulin-Like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment

(2009) T. Kimura et al.   CLINICAL CANCER RESEARCH

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Src as a therapeutic target in men with prostate cancer and bone metastases

(2008) Fred Saad   BJU INTERNATIONAL

Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model

(2008) S. I. Park et al.   CANCER RESEARCH

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

(2008) N Brownlow et al.   LEUKEMIA

Unknown

(2008) Efstathia Papageorgiou et al.   MOLECULAR MEDICINE